48
Participants
Start Date
July 10, 2018
Primary Completion Date
November 10, 2018
Study Completion Date
November 10, 2018
Selatogrel 8 mg
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
Selatogrel 16 mg
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
UZLeuven, Leuven
University Hospital Bern, Bern
Universitätsspital Basel, Basel
Cardiocentro Ticino, Lugano
OLV Ziekenhuis Aalst, Aalst
Galilee Medical Center, Nahariya
Viatris Innovation GmbH
INDUSTRY